<DOC>
	<DOCNO>NCT00923325</DOCNO>
	<brief_summary>Background : - This study companion biology study NIH protocol 08-C-0080 , A Phase II Trial R1507 , Recombinant Human Antibody Insulin-Like Growth Factor-1 Receptor Treatment Patients Recurrent Refractory Ewing Sarcoma , Osteosarcoma , Synovial Sarcoma , Rhabdomyosarcoma Other Sarcomas . - Analysis tumor tissue blood sample patient sarcomas receive treatment experimental drug R1507 may help elucidate biology sarcoma respond certain therapy monoclonal antibody . Objectives : - To study effect time R1507 proteins cell blood tissue patient sarcoma order learn patient respond treatment change occur cell . - To discover possible new treatment cancer . Eligibility : - Participants NIH protocol 08-C-0080 study R1507 treat people various sarcoma . Design : - Patients previously agree part protocol 08-C-0800 blood sample pharmacodynamic study ( blood draw test blood level R1507 body affect R1507 ) additional blood drawn part study . - Patients previously agree pharmacodynamic sample part protocol 08-C-0800 ask give 6 blood sample various time period study . - Pathology slide tissue block obtain protocol 08-C-0800 forward F. Hoffmann-La Roche laboratories analysis .</brief_summary>
	<brief_title>Blood Tissue Study Patients NIH Protocol 08-C-0800</brief_title>
	<detailed_description>Background : - R1507 recombinant , fully human monoclonal IgG1 antibody bind specifically human IGF-1R , result direct inhibition ligand bind loss receptor protein cell surface follow intracellular internalization degradation . - Binding R1507 show inhibit signal transduction proliferation survival function mediate IGF-1R cancer cell . Pre-clinical toxicology safety pharmacology study perform R1507 phase 1 study adult result recommend intravenous dose 9 mg/kg weekly . Phase 1 study ongoing child . - A Phase II study ( SARC011/Roche NO21157 ) : A Phase II Trial R1507 , Recombinant Human Antibody Insulin-Like Growth Factor-1 Receptor treatment patient recurrent refractory Ewing sarcoma , osteosarcoma , synovial sarcoma , rhabdomyosarcoma sarcoma allow opportunity collect tumor tissue serum sample characterize biology sarcomas response IGF1-R monoclonal antibody therapy . Objectives : - To analyze tumor tissue IGF-1R , phosphor ( p ) -IGF-1R , Akt , p-Akt , PTEN , candidate marker related mechanism action R1507 treatment patient sarcoma solid tumor . - To determine whether specific tissue-based assay perform diagnostic specimen allow identification newer prognostic category potentially new molecular target treatment patient sarcoma solid tumor . - To determine whether serum level free IGF-I/II , total IGF-I shed IGF-1R significance outcome patient sarcoma solid tumor . - To identify new treatment target therapy . Further test potential target carry hope expedite translation finding clinical setting . Eligibility : -All patient enrol Phase II study SARC011/Roche NO21157 eligible enrollment . Design : - Unstained tumor tissue slide sample sent confirmatory diagnosis forward analysis Central Pathology Labs New York Leiden Roche Clinical Sample Operations ( CSO ) . Tissue base assay evaluate status IGF-1R downstream pathway perform Roche Central Lab ( HistoGeneX ) NCI Lab . - Serum base assay free serum IGF-I/II , total serum IGF-I shed IGF-1R receptor run use sample obtain prior first dose R1507 specify time treatment describe Table 3.3 . All serum sample ship Roche CSO forward analysis designate laboratory . Serum base assay perform Roche Central Lab ( MicroCoat ) Roche Diagnostics ( Penzberg ) .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<criteria>INCLUSION CRITERIA : All patient enrol Phase II study SARC011/N021157 eligible enrollment . Signed informed consent study accord institutional guideline require . EXCLUSION CRITERIA :</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 27, 2016</verification_date>
	<keyword>Biomarker Analysis</keyword>
	<keyword>Sarcomas</keyword>
	<keyword>Ewing 's Sarcoma</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Rhabdomyosarcoma</keyword>
	<keyword>Synovial Sarcoma</keyword>
	<keyword>Other Sarcoma</keyword>
</DOC>